Puma Biotechnology (PBYI) PT Lowered to $13 at RBC Capital
Tweet
Share
E-mailGet Alerts PBYI Hot Sheet
Price: $9.49 +2.71%
Rating Summary:
5 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
5 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
RBC Capital analyst Kennen MacKay lowered the price target on Puma Biotechnology (NASDAQ: PBYI) to $13.00 (from $23.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
- Viking Holdings (VIK) PT Raised to $121 at UBS Ahead of Q2 Earnings
- Amer Sports Inc. (AS) PT Lowered to $42 at Truist, but 'Momentum continues to surge in a tough macro'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
